MBX Biosciences, Inc. (MBX)

MBX Biosciences Statistics

Total Valuation

MBX Biosciences has a market cap or net worth of $605.67 million. The enterprise value is $415.18 million.

Market Cap	605.67M
Enterprise Value	415.18M

Important Dates

The next estimated earnings date is Thursday, November 6, 2025, before market open.

Earnings Date	Nov 6, 2025
Ex-Dividend Date	n/a

Share Statistics

MBX Biosciences has 44.72 million shares outstanding. The number of shares has increased by 2,182.51% in one year.

Current Share Class	44.72M
Shares Outstanding	44.72M
Shares Change (YoY)	+2,182.51%
Shares Change (QoQ)	+0.10%
Owned by Insiders (%)	2.36%
Owned by Institutions (%)	57.81%
Float	29.39M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	2.22
P/TBV Ratio	2.92
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 19.50, with a Debt / Equity ratio of 0.00.

Current Ratio	19.50
Quick Ratio	19.20
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -56.28% and return on invested capital (ROIC) is -39.40%.

Return on Equity (ROE)	-56.28%
Return on Assets (ROA)	-36.75%
Return on Invested Capital (ROIC)	-39.40%
Return on Capital Employed (ROCE)	-39.39%
Revenue Per Employee	n/a
Profits Per Employee	-$1.79M
Employee Count	43
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -42.23% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-42.23%
50-Day Moving Average	13.99
200-Day Moving Average	11.79
Relative Strength Index (RSI)	44.00
Average Volume (20 Days)	2,770,621

Short Selling Information

The latest short interest is 3.90 million, so 8.72% of the outstanding shares have been sold short.

Short Interest	3.90M
Short Previous Month	4.23M
Short % of Shares Out	8.72%
Short % of Float	13.27%
Short Ratio (days to cover)	1.62

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-86.56M
Pretax Income	-77.02M
Net Income	-77.02M
EBITDA	-86.29M
EBIT	-86.56M
Earnings Per Share (EPS)	-$2.88

Balance Sheet

The company has $224.91 million in cash and $650,000 in debt, giving a net cash position of $224.26 million or $5.02 per share.

Cash & Cash Equivalents	224.91M
Total Debt	650,000
Net Cash	224.26M
Net Cash Per Share	$5.02
Equity (Book Value)	219.24M
Book Value Per Share	6.53
Working Capital	217.43M

Cash Flow

In the last 12 months, operating cash flow was -$70.81 million and capital expenditures -$886,000, giving a free cash flow of -$71.70 million.

Operating Cash Flow	-70.81M
Capital Expenditures	-886,000
Free Cash Flow	-71.70M
FCF Per Share	-$1.60

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

MBX Biosciences does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2,182.51%
Shareholder Yield	-2,182.51%
Earnings Yield	-12.04%
FCF Yield	-11.21%

Analyst Forecast

The average price target for MBX Biosciences is $49.88, which is 268.25% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$49.88
Price Target Difference	268.25%
Analyst Consensus	Strong Buy
Analyst Count	8
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	2